Marinus Pharmaceuticals (MRNS) shares plunged nearly 82% in recent Thursday trading after the company said its phase 3 trial of oral ganaxolone failed to meet its main goal and announced plans to reduce costs and explore alternatives for the business.
Marinus was studying the drug as a treatment for seizures associated with tuberous sclerosis complex in children and adults. The trial failed to achieve "statistical significance" on its primary endpoint of percent change in 28-day frequency of tuberous sclerosis complex-associated seizures, the drugmaker said.
Marinus said it would no longer be developing ganaxolone and would take steps to save costs, including a workforce reduction.
The company also said it has hired Barclays to assist in reviewing its strategic alternatives.
Price: 0.31, Change: -1.38, Percent Change: -81.89
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。